Meeting
2020 ASCO Virtual Scientific Program
Clinical implications of loss of minimal residual disease (MRD) negativity in multiple myeloma.
Authors
Meera Mohan
UAMS Myeloma Center, Little Rock, AR
Meera Mohan , naveen kumar yarlagadda , Dinesh Atwal , Yadav Pandey , Arya Roy , Richa Parikh , James Lopez , Sharmilan Thanendrarajan , Carolina D. Schinke , Daisy Alapat , Frits Van Rhee , Samantha Kendrick , Maurizio Zangari
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8514)
DOI
10.1200/JCO.2020.38.15_suppl.8514
Abstract #
8514
Poster Bd #
414
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Measurable residual disease (MRD) and clonal diversity for multiple myeloma treatment monitoring.
First Author: Joaquin Martinez-Lopez
Poster
2021 ASCO Annual Meeting
Personalized, ctDNA analysis to detect minimal residual disease and identify patients at high risk of relapse with multiple myeloma.
First Author: Binod Dhakal
Poster
2019 ASCO Annual Meeting
Correlation of minimal residual disease negativity (MRD-) with prognosis in high-risk myeloma (HRM).
First Author: Chutima Kunacheewa
Poster
2024 ASCO Annual Meeting
Utilization of tumor-informed circulating tumor DNA in detecting minimal residual disease and guiding adjuvant therapy in liver cancer.
First Author: De-Zhen Guo